Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul-Sep;80(3):605-17.
doi: 10.3797/scipharm.1204-13. Epub 2012 May 22.

Identification and characterization of potential impurities in raloxifene hydrochloride

Affiliations

Identification and characterization of potential impurities in raloxifene hydrochloride

Reguri Buchi Reddy et al. Sci Pharm. 2012 Jul-Sep.

Abstract

During the synthesis of the bulk drug Raloxifene hydrochloride, eight impurities were observed, four of which were found to be new. All of the impurities were detected using the gradient high performance liquid chromatographic (HPLC) method, whose area percentages ranged from 0.05 to 0.1%. LCMS was performed to identify the mass number of these impurities, and a systematic study was carried out to characterize them. These impurities were synthesized and characterized by spectral data, subjected to co-injection in HPLC, and were found to be matching with the impurities present in the sample. Based on their spectral data (IR, NMR, and Mass), these impurities were characterized as Raloxifene-N-Oxide [Impurity: 1]; EP impurity A [Impurity: 2]; EP impurity B [Impurity: 3]; Raloxifene Dimer [Impurity: 4]; HABT (6-Acetoxy-2-[4-hydroxyphenyl]-1-benzothiophene or 6-Hydroxy-2-[4-acetoxyphenyl]-1-benzothiophene) [Impurity: 5]; PEBE (Methyl[4-[2-(piperidin-1-yl)ethoxy]]benzoate) [Impurity: 6]; HHBA (1-[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]ethanone) [Impurity: 7]; 7-MARLF (7-Acetyl-[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-[2-(piperidin-1-yl)ethoxy]phenyl methanone) [Impurity: 8]; of which impurities 5-8 are reported for the first time.

Keywords: Characterization; Evista; Impurities; Isolation; Preparative high performance liquid chromatography; Raloxifene; Synthesis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
HPLC Chromatogram of Raloxifene Hydrochloride Spiked with impurities
Fig. 2
Fig. 2
Structures of Raloxifene and impurities 1–8
Fig. 3
Fig. 3
Possible Formation of Impurities
Fig. 4
Fig. 4
Scheme for the synthesis of Raloxifene
Fig. 5
Fig. 5
Scheme for the synthesis of Impurities

Similar articles

References

    1. Grese TA, Dodge JA. Selective estrogen receptor modulators (SERMs) Curr Pharm Des. 1998;4:71–92. http://www.ncbi.nlm.nih.gov/pubmed/10197034. - PubMed
    1. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med. 1998;217:45–52. http://www.ncbi.nlm.nih.gov/pubmed/9421206. - PubMed
    1. Jones CD, Jevikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA. Antiestrogens. 2: Structure activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl] methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estro-genicity. J Med Chem. 1984;27:1057–1066. http://dx.doi.org/10.1021/jm00374a021. - DOI - PubMed
    1. Sato M, Grese TA, Dodge JA, Bryant HU, Turner CH. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem. 1999;42:1–24. http://dx.doi.org/10.1021/jm980344o. - DOI - PubMed
    1. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud CJ. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835–842. http://dx.doi.org/10.1002/jbmr.5650110615. - DOI - PubMed

LinkOut - more resources